Ropes & Gray represented Singapore-based biotechnology company Gero PTE. LTD. in a joint research and license agreement with Tokyo-based Chugai Pharmaceutical Co, Ltd., a member of Roche Group, to develop novel antibody therapies for age-related diseases. The transaction was announced on July 7.
In the collaboration, Chugai will create novel antibody drug candidates using its antibody engineering technologies for new drug targets discovered by Gero through analysis of human datasets using Gero’s AI target discovery platform.
Under the agreement, Gero grants Chugai exclusive worldwide rights for the creation, research, development, manufacturing and commercialization of antibodies for the identified targets. Gero will receive up to $250 million if predetermined development or sales milestones are achieved and royalties if successful products are launched.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associate Ian Nilsen and included IP transactions counsel Ryan Murphey and life sciences licensing associates Ben Ellingtonand Mallory Ursul.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
